Neurological Sciences

, Volume 34, Issue 5, pp 679–682 | Cite as

TLR91237 T/C and TLR2194 to174 del polymorphisms and the risk of Parkinson’s disease in the Greek population: a pilot study

  • Kallirhoe Kalinderi
  • Sevasti Bostantjopoulou
  • Zoe Katsarou
  • Liana FidaniEmail author
Original Article


Toll-like receptors (TLRs) are important mediators of inflammatory responses by recognition of many pathogen-related molecules and endogenous proteins related to immune activation. Accumulating data have recently pointed out the role of neuroinflammation in Parkinson’s disease (PD) pathogenesis. In the present study, we investigated the potential role of the TLR91237 T/C and TLR2194 to174 del polymorphisms in PD. We studied a total of 333 individuals, 215 Greek patients with sporadic PD and 118 control subjects, using a polymerase chain reaction–restriction fragment length polymorphism method. No statistically significant differences were found between PD patients and control subjects for the TLR91237 T/C genotypes or alleles. Regarding the TLR2196 to174 del polymorphism, the del/del genotype and the del allele were overrepresented in the PD group compared to controls, however, this result did not reach statistical significance (P = 0.087). Further studies investigating the TLR-inflammatory background of PD are awaited to provide important insight into the aetiology of the disease.


Parkinson’s disease Toll-like receptors Polymorphism 


  1. 1.
    Zimprich A (2011) Genetics of Parkinson’s disease and essential tremor. Curr Opin Neurol 24:318–323 (review)PubMedCrossRefGoogle Scholar
  2. 2.
    Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics 7:354–365PubMedCrossRefGoogle Scholar
  3. 3.
    Chang ZL (2010) Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 59:791–808 (review)PubMedCrossRefGoogle Scholar
  4. 4.
    Yu JT, Mou SM, Wang LZ, Mao CX, Tan L (2011) Toll-like receptor 2 −196 to −174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer’s disease. J Neuroinflamm 8:136CrossRefGoogle Scholar
  5. 5.
    Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S (2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA 108:6632–6637PubMedCrossRefGoogle Scholar
  6. 6.
    Hamann L, Glaeser C, Hamprecht A, Gross M, Gomma A, Schumann RR (2006) Toll-like receptor (TLR)-9 promotor polymorphisms and atherosclerosis. Clin Chim Acta 364:303–307PubMedCrossRefGoogle Scholar
  7. 7.
    Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, Hagemann T, Diaz-Lacava A, Baurecht HJ, Klopp N, Wagenpfeil S, Behrendt H, Bieber T, Ring J, Illig T, Weidinger S (2007) Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 62:766–772PubMedCrossRefGoogle Scholar
  8. 8.
    Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki M, Arinami T (2004) An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 34:177–183PubMedCrossRefGoogle Scholar
  9. 9.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  10. 10.
    Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17:1–14 (review)PubMedCrossRefGoogle Scholar
  11. 11.
    McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291PubMedCrossRefGoogle Scholar
  12. 12.
    Tansey M, McCoy M, Frank-Cannon T (2007) Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1–25PubMedCrossRefGoogle Scholar
  13. 13.
    Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, Kay DM, Doheny KF, Paschall J, Pugh E, Kusel VI, Collura R, Roberts J, Griffith A, Samii A, Scott WK, Nutt J, Factor SA, Payami H (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42:781–785PubMedCrossRefGoogle Scholar
  14. 14.
    Béraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA (2011) α-Synuclein alters Toll-like receptor expression. Front Neurosci 5:80PubMedCrossRefGoogle Scholar
  15. 15.
    Carty M, Bowie AG (2011) Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 81:825–837 (review)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Kallirhoe Kalinderi
    • 1
  • Sevasti Bostantjopoulou
    • 2
  • Zoe Katsarou
    • 2
  • Liana Fidani
    • 1
    Email author
  1. 1.Department of General BiologyMedical School, Aristotle University of ThessalonikiThessalonikiGreece
  2. 2.Third Department of NeurologyG. Papanikolaou Hospital, Aristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations